Treatment of Psoriasis With IBD May Require Higher Doses of Risankizumab
A case report of a man with plaque psoriasis and comorbidities that include psoriatic arthritis and ulcerative colitis.
All articles by Rose Reeb
Risankizumab After Guselkumab Failure as Effective as Risankizumab Alone
A novel study investigates an in-class IL-23 inhibitor switch from guselkumab to risankizumab for patients with psoriasis.
Skin Care Products May Reduce Incidence of Rosacea in Patients With Acne
The classification and severity of acne and rosacea in women was characterized and the co-occurrence triggers assessed.
25% TCA Peel and Dermabrasion Significantly Improves Acne Scar Appearance
The effectiveness and safety of 25% trichloroacetic acid (TCA) alone or followed by manual dermasanding for the treatment of mild and moderate acne scars was evaluated.
Sleep Disturbance in Adolescence Linked to Opioid Misuse in Adulthood
Adolescent sleep deficiency as an increased future risk for prescription opioid misuse was examined in a large nationally, representative database designed to track health behaviors and outcomes from adolescence to early adulthood.
Brodalumab Treatment for Psoriasis Safe and Effective in Real-World Setting
Brodalumab’s safety and effectiveness in real-world clinical settings for treatment of psoriasis was evaluated.
SA-CIDES Reliable for Estimate of Involved BSA in Psoriasis and Eczema
Data was analyzed to determine if the SA-CIDES could accurately be used in the estimation of involved body surface area for patients with psoriasis and eczema.
Ustekinumab May Be Associated With SCE in High Cardiovascular Risk Patients
The association of ustekinumab therapy initiation and increased risk for severe cardiovascular events was assessed.
Dysglycemia, Diabetes a Common Comorbidity in Patients With Hidradenitis Suppurativa
The utility of screening with hemoglobin A1c (HbA1c) in a dermatology clinic to detect
undiagnosed dysglycemia and diabetes in patients with hidradenitis suppurativa was evaluated.
Secukinumab Effective in Real-Life Patients With Moderate-Severe Psoriasis
The effectiveness and safety of secukinumab in patients with moderate-severe psoriasis vulgaris in a large, 52-week, real-world setting was assessed.
-
Loading...
-
Loading...
Next post in Psoriasis
